TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-5.63%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.54B
AUM Growth
+$2.54B
(-11%)
Cap. Flow
-$63M
Cap. Flow
% of AUM
-2.48%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
28
Reduced
33
Closed
3
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$14.8M |
| 2 |
Intuitive Surgical
ISRG
|
$9.75M |
| 3 |
AstraZeneca
AZN
|
$8.86M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$8.43M |
| 5 |
Boston Scientific
BSX
|
$8.42M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$24M |
| 2 |
McKesson
MCK
|
$14.8M |
| 3 |
Eli Lilly
LLY
|
$11.5M |
| 4 |
Medtronic
MDT
|
$9.78M |
| 5 |
Waters Corp
WAT
|
$8.23M |
Sector Composition
| 1 | Healthcare | 95.42% |
| 2 | Real Estate | 3.13% |
| 3 | Industrials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Medtronic
MDT
$119B
| $29.3M | 1.15% | 326,172 -108,968 | -25% | -$9.78M |
|
27
Biogen
BIIB
$19.4B
| $27.7M | 1.09% | 135,639 | – | – |
|
28
Jazz Pharmaceuticals
JAZZ
$7.75B
| $26.2M | 1.03% | 167,899 +27,426 | +20% | +$4.28M |
|
29
Zoetis
ZTS
$69.3B
| $25.2M | 0.99% | 146,714 +5,547 | +4% | +$953K |
|
|
SYNH
30
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $21.7M | 0.85% | 302,945 -78,625 | -21% | -$5.64M |
|
|
31
Intuitive Surgical
ISRG
$170B
| $21.3M | 0.84% | 106,176 +48,570 | +84% | +$9.75M |
|
32
HCA Healthcare
HCA
$94.5B
| $20.9M | 0.82% | 124,303 | – | – |
|
33
Alnylam Pharmaceuticals
ALNY
$58.5B
| $18.7M | 0.74% | 128,414 -30,192 | -19% | -$4.4M |
|
34
Idexx Laboratories
IDXX
$51.8B
| $18.6M | 0.73% | 52,910 -8,307 | -14% | -$2.91M |
|
35
IQVIA
IQV
$32.4B
| $18.3M | 0.72% | 84,303 -13,851 | -14% | -$3.01M |
|
36
Becton Dickinson
BDX
$55.3B
| $18.2M | 0.72% | 73,930 | – | – |
|
37
Icon
ICLR
$13.8B
| $17.6M | 0.69% | 81,375 -6,862 | -8% | -$1.49M |
|
38
United Therapeutics
UTHR
$13.8B
| $17M | 0.67% | 72,206 | – | – |
|
39
Welltower
WELL
$113B
| $16.7M | 0.66% | 203,083 | – | – |
|
40
Neurocrine Biosciences
NBIX
$13.8B
| $16.4M | 0.64% | 168,108 +43,499 | +35% | +$4.24M |
|
41
Edwards Lifesciences
EW
$47.8B
| $16.3M | 0.64% | 171,388 -5,800 | -3% | -$552K |
|
42
Sarepta Therapeutics
SRPT
$1.78B
| $15.9M | 0.63% | 212,165 -15,532 | -7% | -$1.16M |
|
|
43
SPDR S&P Biotech ETF
XBI
$5.07B
| $15.5M | 0.61% | 209,154 +113,505 | +119% | +$8.43M |
|
44
Zimmer Biomet
ZBH
$21B
| $14.9M | 0.59% | 142,044 | – | – |
|
45
ResMed
RMD
$40.2B
| $14.9M | 0.58% | 70,999 | – | – |
|
46
Rallybio
RLYB
$22.4M
| $14.6M | 0.57% | 1,931,120 -263,890 | -12% | -$1.99M |
|
47
argenx
ARGX
$43.6B
| $14.6M | 0.57% | 38,456 | – | – |
|
48
Novo Nordisk
NVO
$251B
| $14.5M | 0.57% | 130,523 -23,000 | -15% | -$2.56M |
|
49
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $14.5M | 0.57% | 113,230 | – | – |
|
50
Guardant Health
GH
$8.41B
| $14.2M | 0.56% | 351,484 | – | – |
|